Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of PNT2258 in Richter's Transformation
2015-001814-85Phase 2Completed
- Sponsor
- Sierra Oncology
- Start
- Oct 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL) and Richter's syndrome (RS), sponsored by Sierra Oncology. Primary endpoint: Overall response rate (ORR). Started Oct 2015; status: completed.
02
Drugs
PNT2258
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Richter's syndrome (RS)
Beyond the preview
Go deeper on 2015-001814-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001814-85.